Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) gapped up prior to trading on Tuesday . The stock had previously closed at $0.28, but opened at $0.32. Protalix Biotherapeutics shares last traded at $0.30, with a volume of 9,625 shares traded.
A number of equities analysts recently weighed in on PLX shares. Zacks Investment Research upgraded Protalix Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, October 15th. HC Wainwright set a $3.00 price objective on shares of Protalix Biotherapeutics and gave the company a “buy” rating in a research note on Friday, October 18th.
Protalix Biotherapeutics (NYSEAMERICAN:PLX) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.02. The company had revenue of $14.25 million during the quarter, compared to the consensus estimate of $11.60 million. During the same quarter in the prior year, the firm earned ($0.10) earnings per share.
A hedge fund recently raised its stake in Protalix Biotherapeutics stock. Wedbush Securities Inc. grew its holdings in Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) by 70.6% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 145,000 shares of the company’s stock after buying an additional 60,000 shares during the period. Wedbush Securities Inc. owned 0.10% of Protalix Biotherapeutics worth $30,000 as of its most recent filing with the Securities & Exchange Commission.
About Protalix Biotherapeutics (NYSEAMERICAN:PLX)
Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease.
Featured Story: Exchange-Traded Funds (ETFs)
Receive News & Ratings for Protalix Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.